11-29-2023 12:11 PM CET | Health & Medicine

Press release from: Coherent Market Insights

Click here to check the original post on openPR.

The Nanobodies Market is estimated for 2023 for the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Nanobodies are single variable domains of heavy-chain antibodies that are derived from camelid ungulates like llamas, camels and alpacas. They are used for research and diagnostic applications in cell imaging, protein analysis and detect various biomolecules.

Market Dynamics:

The nanobodies market is expected to witness significant growth owing to rising prevalence of chronic diseases globally. According to the WHO, chronic diseases accounted for approximately 60% of all reported deaths in the world in 2020. In addition, increasing funding for R&D activities of monoclonal antibody therapeutics is also expected to support the nanobodies market growth over the forecast period. For instance, the U.S. National Institutes of Health (NIH) invested around US$ 32 billion towards biomedical research including development of therapeutic antibodies in 2021. Furthermore, nanobodies offer advantages over conventional antibodies such as high solubility, small size, ease of production and low immunogenicity which further stimulates their demand in pharmaceutical and diagnostic applications.

Receive Sample of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1680

** Note - This Report Sample Includes:

‣ Brief Overview to the research study.

‣ Table of Contents The scope of the study's coverage

‣ Leading market participants

‣ Structure of the report's research framework

‣ Coherent Market Insights' research approach

Major companies in Nanobodies Market are:

✤ Merck KGaA
✤ Sanofi
✤ AlpalifeB Inc
✤ GenScript
✤ Novartis International AG
✤ Taisho Pharmaceutical Holdings Co., Ltd.,
✤ Sino Biological Inc.
✤ GeneMedi
✤ Biocytogen
✤ Abnova Corporation
✤ NanoTag Biotechnologies
✤ Avillion LLP
✤ Capra Science
✤ Numab Therapeutics
✤ CUSABIO TECHNOLOGY LLC
✤ Proteintech Group Inc.
✤ GT Biopharma Inc.
✤ Confo Therapeutics
✤ R&D Systems Inc.
✤ Abcepta Biotech Ltd. Co.

Note: Major Players are sorted in no particular order.

Market Driver:Increasing Prevalence of Chronic and Infectious Diseases

The prevalence of chronic and infectious diseases is increasing rapidly across the globe. Diseases like cancer, cardiovascular diseases, inflammatory diseases, diabetes etc. have become very common. At the same time, infectious diseases like influenza, HIV/AIDS, hepatitis, covid etc. keep emerging and re-emerging posing serious threats. Nanobodies have emerged as very promising therapeutic agents for treating such diseases due to their high affinity, specificity and stability. Many companies are engaged in developing nanobody based drugs for conditions like cancer, cardiovascular diseases, covid etc. This rising disease burden is expected to significantly drive the demand for nanobody therapeutics in the coming years.

Market Driver:Advantages of Nanobodies Over Conventional Antibody Therapies

Nanobodies have certain unique advantages over conventional monoclonal antibody therapies which is boosting their demand and uptake in the therapeutic landscape. Key advantages include - smaller size which allows better tissue penetration, ability to target 'undruggable' targets, low production cost, higher stability at varying conditions of pH, temperature etc. These advantages make nanobodies a feasible alternative to conventional antibodies for various therapeutic and diagnostic applications. Many pharmaceutical companies are replacing traditional antibodies with nanobodies in their drug development pipelines to exploit these advantages. This growing recognition of nanobodies' benefits is a major factor propelling the nanobodies market growth.

Market Restrain:Technical Challenges in Production and Scale Up

While nanobodies offer several promising applications, their production and scale up still pose some technical challenges which can hinder the broader nanobodies market potential. Key among these is difficulty in achieving higher expression levels of nanobodies during fermentation. As nanobodies lack the Fc portion of conventional antibodies, some technologies used for antibody production cannot be applied for nanobodies. Manufacturing processes for nanobodies also require additional optimization steps. Addressing these technical hurdles in abundant production of nanobodies through cost-effective methods is crucial for commercial success of nanobody therapeutics. Unless resolved, these challenges can significantly restrain the market in coming years.

Market Opportunity: Expanding Applications Outside Therapeutics

Besides therapeutics, nanobodies are increasingly finding applications in other domains like diagnostics, bioanalytical research, veterinary science, agricultural biotechnology etc. In diagnostics area, nanobodies are being evaluated as detection reagents for point-of-care tests for infectious diseases, cardiac markers etc. due to their robust stability. In research, nanobodies are exploited for applications like protein analysis, tissue staining, immuno-PCR etc. Vets are exploring nanobody usage in animal healthcare. Several startups are coming up with novel ideas like nanobody-based pest controls for agriculture. Successful commercialization of any such non-therapeutic application could unlock new revenue streams for nanobody market participants going forward.

Market Trend:Increasing Adoption of Multivalent and Multispecific Nanobodies

Traditionally most research on nanobodies centered around monovalent formats. However, generating multivalent or multispecific constructs by combining different nanobodies is emerging as an important trend. Linked variable regions of different nanobodies can generate bispecific or trispecific molecules with dual/multiple target bindings. Such engineered multivalent nanobodies exhibit enhanced avidity, improved stability and differentiated modes of action compared to monovalent molecules. They are promising candidates for various refractory diseases. Many pharma companies are now focusing on developing multivalent nanobody constructs against targets like interleukin-23 and fibroblast growth factor. Their potential advantages are likely to significantly expand the scope of nanobody therapeutics in the coming years.